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The aims of this study were to investigate the role of vascular invasion (blood and lymphatic), vessel density
and the presence of tumour-associated macrophages as prognostic markers in 202 cutaneous melanoma
patients. Sections of primary melanoma were stained with lymphatic-specific antibody D2-40 to assess
lymphatic vessel invasion and density in intratumoural and peritumoural areas; an antibody against endothelial
marker CD34 was used to determine blood vessel invasion and density, and an antibody against CD68 was used
to determine macrophage counts. Immunohistochemically determined vascular invasion (combined blood and
lymphatic) was compared with that determined using haematoxylin and eosin (H&E) staining. The use of
immunohistochemistry increased detection of vascular invasion from 8–30% of patients, and histological exam
of H&E-stained tissue was associated with a false positive rate of 64%. Lymphatic vessel invasion occurred at a
much higher frequency than blood vessel invasion (27 and 4% of patients, respectively). Although
immunohistochemically detected vessel invasion was significantly associated with histological markers of
adverse prognosis, such as increased Breslow thickness, ulceration and mitotic rate (all Po0.001), no
associations with relapse-free or overall survival were observed. High macrophage counts were significantly
associated with markers of aggressive disease, such as Breslow thickness, ulceration and mitotic rate
(Po0.001, Po0.001, P¼ 0.005, respectively), and lymphatic vessel invasion and high microvessel density
(P¼ 0.002 and P¼ 0.003, respectively). These results suggest that vascular invasion is more accurately detected
using immunohistochemistry and occurs predominantly via lymphatic vessels. The association of vessel
characteristics with histological characteristics of the primary melanoma provides evidence for their biological
importance in melanoma, but that they were not associated with clinical outcome attests to the value of existing
histological prognostic biomarkers. We note that a high macrophage count may be associated with
neovascularisation and primary tumour growth, and may also promote invasion through lymphatic vessels.
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Cutaneous melanoma is the most potentially lethal
form of skin cancer and a number of poor prognostic
factors have been identified, such as increased Breslow
thickness, tumour ulceration, increased mitotic rate
and positive sentinel node biopsy.1 These measures
are incorporated into the American Joint Committee
on Cancer staging system, which explains a large
part, but not all, of the variance in survival for
melanoma patients.1 Vascular invasion, encompassing
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both blood and lymphatic vessel invasion, is an
important characteristic of various tumour types
and is an independent prognostic factor in certain
cancers, such as breast cancer.2 Tumour cells have
the ability to spread through lymphatic vessels to
lymph nodes, making lymphatic vessels important
in the initial metastatic cascade of cancer.
In melanoma, the significance of lymphatic inva-
sion and vessel density have been investigated in a
small number of studies using immunohistochem-
istry as a more sensitive method of assessment,
using various specific lymphatic markers such as
D2-40 and LYVE-1; however, controversy remains
over aspects of its clinical relevance. Low lymphatic
vessel density has been shown to be associated with
both adverse3 and improved patient survival.4,5 In
addition, high lymphatic vessel density has been
associated with metastatic spread,6–8 but also with
the absence of vascular invasion.3 Lymphatic vessel
invasion has been previously associated with various
clinicopathological variables, such as ulceration9 and
increased Breslow thickness,10,11 but also clinical
outcome, such as metastases and overall survival.9,11,12
Evidence for an association between lymphatic vessel
invasion and sentinel node biopsy positivity remains
inconclusive, with studies containing varying rela-
tively small numbers of patients (27–96 patients)
showing either a significant association9,10,12,13 or no
association.14,15 Haematoxylin and eosin (H&E)-deter-
mined vascular invasion in primary melanoma has
been shown to be an independent prognostic factor for
melanoma survival16–18 and sentinel node biopsy
positivity.19 The presence of macrophage infiltration
of the invasive front of melanoma tumours has been
shown to be associated with poor overall survival,20
and the presence of intratumoural macrophages are
associated with survival in sinonasal melanoma;21
however, its presence has not been investigated in
association with vascular invasion. Interestingly,
metastasis in melanoma xenograft models has
recently been associated with microvessel density.22
The first aim of this study was to investigate the
role of lymphatic and blood vessel invasion, and
lymphatic and microvessel density as prognostic
biomarkers, using immunohistochemistry in mela-
noma patients. The second aim of this study was to
investigate the topography and characteristics of
lymphatic and blood vessels in a large cohort of
melanoma patients, and to analyse their association
with clinicopathological variables and clinical outcome.
Finally, we sought to investigate the role that tumour-
associated macrophages may have in these processes
by investigating the associations between macrophage
counts and the characteristics of the vessels.
Materials and methods
Patients and Specimens
Patients with cutaneous melanoma of Breslow
thickness X0.75mm, having undergone sentinel
node biopsy, were recruited to a multi-centre case–
control study designed to identify predictors of
sentinel node biopsy positivity and outcome.23 This
study was conducted on 202 paraffin-embedded
archival specimens obtained from patients having
had a sentinel node biopsy between 1994 and 2006
at five UK centres. Ethical approval for the study
was granted by Leeds (East) REC (06/Q1206/149).
Clinical data were taken from patient case notes.
The median age of the patients was 53 years, with a
range of 14–88 years; 65% (132/202) had a positive
sentinel lymph node biopsy; 49% (99/202) of the
patients were female. Breslow thickness, ulceration,
mitotic rate, the presence of microsatellites and
histological subtype, were all recorded by one expert
melanoma pathologist (MC). A total of 32% (62 out
of 196) of patients relapsed and 22% of patients died
(45 out of 200) within this cohort, and the mean
follow-up time was 38 months. Relapse-free survival
was calculated from the date of the initial surgery to
the first relapse, or from the date of the initial
surgery to the last date known to have not relapsed
for those censored. Overall survival time was
calculated from the date of the initial surgery to
death, or from date of the initial surgery to last date
known to be alive for those censored.
Immunohistochemistry
For visualisation of vessels and macrophages, three
consecutive formalin-fixed paraffin-embedded ar-
chival sections from each specimen were stained
with antibodies against CD34 (AbD Serotec, Kidling-
ton, UK) and CD68 (Abcam, Cambridge, UK) to stain
blood vessels and macrophages, respectively. Anti-
body D2-40 (Covance SIGNET, NJ, USA) was used to
stain lymphatic vessels. Tissue was stained as
previously described.24,25 Briefly, 4-mm sections
were deparaffinised in histolene, followed by rehy-
dration in ethanol. For CD34 and CD68 antibodies,
antigen retrieval was performed in 0.01mol/l
sodium citrate buffer (pH6) in a microwave. Endo-
genous peroxidase activity was blocked in 0.01%
hydrogen peroxide in methanol, and non-specific
binding was blocked using normal swine serum
(Dako, Glostrup, Denmark). Primary antibodies
(CD34 1:500; D2-40 1:100; CD68 1:100) were incu-
bated on the tissue for 1 h before incubation with
biotinylated secondary antibody according to the
manufacturer’s instructions (StreptABComplex/HRP
Duet; Dako). CD34 and D2-40 reactions were devel-
oped with 3,30 diaminobenzidine as the chromo-
genic peroxidase substrate, and CD68 reactions were
developed with permanent red substrate (Dako) to
distinguish macrophages from melanocytes. Sec-
tions were counterstained with Gills formula Hae-
matoxylin (Vector Laboratories, Peterborough, UK),
dehydrated and fixed before mounting with DPX, or
Glycergel mounting medium for CD68-stained sec-
tions. Sections of tonsil or placental tissue were
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included as controls, where primary antibody was
omitted for negative controls. In addition, a further
consecutive section was stained using H&E for
comparison against immunostained tissues.
Assessment of Microvessel Density and Macrophage
Count
Microvessel density and the number of macrophages
in each tissue section were counted using the
‘hotspot’ Chalkley 25-point method in three areas,
with an average value used for analysis as pre-
viously described.24–26 Slides (20%) were examined
by two independent assessors blinded to clinico-
pathological data and scores.
Assessment of Lymphatic Vessel Density
Lymphatic vessel density was assessed by counting
all positively stained vessels in the whole section as
previously described.27 Briefly, the sections were
divided into two areas, intratumoural and peritu-
moural, and positive vessels were counted across
the total tumour area, which was determined in
mm2 by approximating tumour size by counting
fields of view, each representing a surface area of
154mm2. Lymphatic vessel density in each area was
determined by dividing the sum of lymphatic
vessels in that area by the total surface area,
presented as vessels per mm2. Total lymphatic
vessel density for each specimen is the sum of both
intratumoural and peritumoural lymphatic vessel
densities. Slides (30%) were examined by two
independent assessors blinded to clinicopathologi-
cal data and scores.
Assessment of Vascular Invasion
H&E assessment was initially performed to identify
those tumours as vascular invasion positive, nega-
tive or probable. Using immunohistochemically
stained sections, lymphatic vessel invasion was
determined as the presence of tumour cells within
a D2-40-stained vessel. Blood vessel invasion was
determined as the presence of tumour cells in
vessels stained with anti-CD34 antibody, but not
using D2-40 antibody. Sections with either lympha-
tic vessel invasion or blood vessel invasion were
classed as vascular invasion positive. All probable
lymphatic vessel invasions were reviewed by a
consultant pathologist (MC and/or IOE). Vascular
invasion was categorised as negative, probable and
positive, and for analysis, probable invasions were
grouped with the positive grouping. The frequency
of vascular invasion assessed by immunohistochem-
istry was compared with H&E staining; false
positives were recorded when H&E-determined
vascular invasion was shown to be an artefact
by immunohistochemistry; false negatives were
reported as negative by H&E, but immunohisto-
chemistry revealed vascular invasion to be present.
The location of lymphatic vessel invasion was also
topographically assessed as within the intratumour-
al or peritumoural areas.
Statistical Analysis
Some tumours were not scored due to a lack of
peritumoural or missing tissue. To test for associa-
tions between vascular invasion, vessel density and
clinicopathological variable data, Pearson’s w2-test of
association was used, or Fisher’s exact test if a cell
count was o5. Vessel density and macrophage
counts were assessed by categorising data as high
or low around the median value. Overall survival
and relapse-free survival curves were plotted ac-
cording to the Kaplan–Meier method and assessed
further, using multivariate survival analysis using
Cox regression. An arbitrary significance level of 1%
was used. Statistical analysis was carried out using
STATA version 10 (StataCorp 2007, Stata statistical
software: Release 10, College Station, TX: Stata-
CorpLP) and SPSS software version 17.
Results
Comparison of Immunohistochemistry and H&E
Staining Methodologies
The presence of vascular invasion (either blood or
lymphatic) determined by immunohistochemistry
and H&E staining was directly compared in con-
secutive sections. In this study, immunohistochem-
istry detected any vascular invasion (both blood and
lymphatic) in 30% of cases (55 out of 184), whereas
H&E staining detected vascular invasion in 8% of
cases (16 out of 199). Of the vascular invasion
detected by immunohistochemistry, the majority
(85%; 47 out of 55) was solely via lymphatic vessels,
5% of tumours had both lymphatic and blood vessel
invasion (3 out of 55), and 9% (5 out of 55) of
tumours had blood vessel invasion alone.
Vessel invasion in the cases, which had both H&E
and immunohistochemistry results available (184
cases), was compared. In this group of cases, 14
patients had vascular invasion evident in sections
stained by H&E, 9 of which were shown to be false
positives by immunohistochemistry (64%). Of the
170 cases negative for vascular invasion determined
by H&E, 50 were false negative (29%). Examples of
H&E and immunohistochemistry staining are shown
in Figure 1.
Relationship between Vascular Invasion and
Clinicopathological Data
Intratumoural, peritumoural, or any lymphatic in-
vasion (a measure resultant from combined intratu-
moural and peritumoural invasion) was observed in
Macrophage and melanoma
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17% (33 out of 191), 15% (27 out of 181), 27% (50
out of 186) of cases, respectively. Blood vessel
invasion occurred in 4% (8 out of 190) cases, 3 of
which also had lymphatic vessel invasion. The
presence of intratumoural lymphatic vessel invasion
was positively associated with increased stage
(Fisher’s exact test, P¼ 0.004), increased Breslow
thickness (Fisher’s exact test, Po0.001), the pre-
sence of ulceration (w2¼ 14.69, d.f.¼ 1, Po0.001),
high mitotic rate (Fisher’s exact test, Po0.001) and
the presence of microsatellites (w2¼ 6.18, d.f.¼ 1,
P¼ 0.01) in addition to nodular histological subtype
(w2¼ 18.94, d.f.¼ 2, Po0.001) (Table 1). Peritum-
oural lymphatic vessel invasion was positively
Figure 1 Photomicrographs of tissue stained with D2-40 (lymphatic vessels), anti-CD34 (pan-vascular marker), anti-CD68 (macrophage
marker), and haematoxylin and eosin (H&E) from two tumours (a–d tumour 1, c–h tumour 2). Examples are given of a true positive
determined in H&E-stained tissue (tumour 1) and an example of a false negative in H&E-stained tissue (tumour 2). Tumour one; (a) vessel
invasion determined in H&E-stained tissue; (b) invasion occurs in D2-40-stained lymphatic vessel; (c) invasion is visible in a vessel
stained with anti-CD34; (d) anti-CD68-stained macrophage are observed around the invasion. Tumour 2; (e) vessel invasion not visible in
H&E-stained tissue; (f) invasion occurs in D2-40-stained lymphatic vessel; (g) consecutive section stained with anti-CD34; (h) anti-CD68-
stained tissue. All images are shown at 20 magnification.
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associated with increased stage (Fisher’s exact test,
Po0.001), increased Breslow thickness (w2¼ 13.08,
d.f.¼ 2, P¼ 0.001) and the presence of ulceration
(w2¼ 16.99, d.f.¼ 1, Po0.001), in addition to nodu-
lar histological subtype (Fisher’s exact test,
Po0.001; Table 1). Unlike intratumoural lymphatic
vessel invasion, peritumoural lymphatic vessel
invasion was not associated with mitotic rate or
the presence of microsatellites. When analysed as
any lymphatic vessel invasion, positive associations
were observed with increased stage (Fisher’s exact
test, Po0.001), increased Breslow thickness
(w2¼ 29.27, d.f.¼ 2, Po0.001), the presence of
ulceration (w2¼ 22.59, d.f.¼ 1, Po0.001), high mito-
tic rate (w2¼ 18.90, d.f.¼ 2, Po0.001), the presence
of microsatellites (w2¼ 6.64, d.f.¼ 1, P¼ 0.01) and
nodular histological subtype (w2¼ 28.47, d.f.¼ 2,
Po0.001; Table 1). Blood vessel invasion was not
significantly associated with any clinicopathol-
ogical variable (Table 2). Immunohistochemically
determined vascular invasion (intratumoural, peri-
tumoural lymphatic vessel, or blood vessel inva-
sion), was positively associated with increased stage
(Fisher’s exact test, Po0.001), increased Breslow
thickness (w2¼ 26.58, d.f.¼ 2, Po0.001), the pre-
sence of ulceration (w2¼ 19.51, d.f.¼ 1, Po0.001)
Figure 1 Continued.
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Table 1 The table shows the association between intra- and peritumoural lymphatic vessel invasion, any lymphatic invasion, and
invasion of any immunohistochemically stained vessel (both blood and lymphatic) with clinicopathological variables in melanoma
Category Lymphatic vessel invasion Any vessel invasion
Intratumoural n (%) Peritumoural n (%) Any n (%) (IHC determined) n (%)
Absent Present P-value Absent Present P-value Absent Present P-value Absent Present P-value
Gender
Female (n¼99) 78 (49) 14 (42) 0.47 76 (49) 13 (48) 0.91 68 (50) 23 (46) 0.63 64 (50) 25 (45) 0.61
Male (n¼ 103) 80 (51) 19 (58) 78 (51) 14 (52) 68 (50) 27 (54) 65 (50) 30 (55)
Sentinal node biopsy (SNB)
Negative (n¼70) 58 (37) 8 (24) 0.17 58 (38) 8 (30) 0.42 53 (39) 13 (26) 0.10 49 (38) 14 (25) 0.10
Positive (n¼132) 100 (63) 25 (76) 96 (62) 19 (70) 83 (61) 37 (74) 80 (62) 41 (75)
Relapse status
No (n¼ 134) 110 (71) 18 (58) 0.16 109 (72) 15 (56) 0.08 98 (73) 29 (60) 0.10 93 (73) 31 (58) 0.05
Yes (n¼62) 45 (29) 13 (42) 42 (28) 12 (44) 36 (27) 19 (40) 34 (27) 22 (41)
Staging
IA/IB (n¼ 43) 38 (25) 2 (6) 0.004* 39 (26) 1 (4) o0.001* 37 (28) 3 (6) o0.001* 35 (28) 3 (6) o0.001*
IIA (n¼11) 10 (7) 1 (3) 10 (7) 1 (4) 9 (7) 2 (4) 8 (6) 2 (4)
IIB/IIC (n¼ 12) 7 (5) 4 (12) 6 (4) 5 (19) 5 (4) 6 (12) 5 (4) 6 (12)
IIIA (n¼88) 71 (47) 13 (39) 69 (47) 8 (31) 62 (47) 17 (35) 59 (47) 20 (38)
IIIB (n¼41) 26 (17) 13 (39) 24 (16) 11 (42) 18 (14) 20 (42) 18 (14) 21 (40)
Number of positive nodes
0 (n¼ 70) 58 (37) 8 (24) 0.34* 58 (38) 8 (30) 0.05* 53 (39) 13 (26) 0.16* 49 (38) 14 (25) 0.09*
1 or 2 (n¼123) 93 (59) 23 (70) 91 (59) 15 (56) 78 (57) 33 (66) 76 (59) 36 (65)
X3 (n¼9) 7 (4) 2 (6) 5 (3) 4 (15) 5 (4) 4 (8) 4 (3) 5 (9)
Melanoma site
Trunk (n¼73) 63 (40) 9 (27) 0.43* 59 (38) 8 (30) 0.77* 56 (41) 13 (26) 0.26* 53 (41) 16 (29) 0.46*
Leg (n¼ 67) 52 (33) 11 (33) 48 (31) 11 (41) 42 (31) 19 (38) 39 (30) 21 (38)
Arm (n¼ 45) 32 (20) 10 (30) 35 (23) 6 (22) 28 (21) 14 (28) 28 (22) 14 (25)
Head/neck (n¼17) 11 (7) 3 (9) 12 (8) 2 (7) 10 (7) 4 (8) 9 (7) 4 (7)
Histological subtype
Superficial spreading
(n¼ 141)
120 (82) 15 (45) o0.001* 121 (82) 11 (46) o0.001* 111 (85) 22 (47) o0.001 106 (85) 24 (48) o0.001
Nodular (n¼ 37) 20 (14) 14 (42) 19 (13) 11 (46) 13 (10) 20 (43) 13 (10) 20 (40)
Other (n¼ 12) 7 (5) 4 (12) 8 (5) 2 (8) 6 (5) 5 (11) 5 (4) 6 (12)
Breslow thickness (mm)
p1 (n¼94) 84 (53) 4 (12) o0.001* 82 (53) 5 (19) 0.001 79 (58) 8 (16) o0.001 75 (58) 10 (18) o0.001
41 p2 (n¼ 79) 58 (37) 17 (52) 55 (36) 14 (52) 45 (33) 27 (54) 42 (33) 30 (55)
42 p4 (n¼ 29) 16 (10) 12 (36) 17 (11) 8 (30) 12 (9) 15 (30) 12 (9) 15 (27)
Ulceration
No (n¼ 145) 121 (80) 15(47) o0.001 119 (80) 11 (42) o0.001 109 (83) 23 (48) o0.001 103 (82) 26 (50) o0.001
Yes (n¼50) 31 (20) 17 (53) 29 (20) 15 (58) 22 (17) 25 (52) 22 (18) 26 (50)
Mitotic rate (per mm2)
o3 (n¼68) 62 (39) 2 (6) o0.001* 57 (37.3) 5 (18.5) 0.09 55 (41) 7 (14) o0.001 52 (41) 8 (15) o0.001
3–7 (n¼ 62) 52 (33) 6 (18) 47 (30.7) 8 (29.6) 43 (32) 13 (26) 41 (32) 14 (25)
47 (n¼ 71) 43 (37) 25 (76) 49 (32.0) 14 (51.9) 37 (27) 30 (60) 35 (27) 33 (60)
Perineural infiltration
No (n¼ 186) 143 (98) 32 (100) 1.00* 141 (98.6) 25 (96.2) 0.40* 124 (98) 47 (98) 1.00* 118 (98) 50 (98) 1.00*
Yes (n¼3) 3 (2) 0 (0) 2 (1.4) 1 (3.8) 2 (2) 1 (2) 2 (2) 1 (2)
Regression
No (n¼ 171) 128 (82) 32 (97) 0.03* 131 (86.2) 19 (70.4) 0.04 114 (85) 41 (82) 0.61 107 (84) 46 (84) 0.917
Yes (n¼29) 28 (18) 1 (3) 21 (13.8) 8 (29.6) 20 (15) 9 (18) 20 (16) 9 (16)
Microsatellites
No (n¼ 163) 132 (90) 23 (74) 0.01 126 (88.7) 21 (80.8) 0.26 115 (91) 36 (77) 0.01 110 (92) 38 (76) 0.006
Yes (n¼25) 14 (10) 8 (26) 16 (11.3) 5 (19.2) 11 (9) 11 (23) 10 (8) 12 (24)
Tumour infiltrating lymphocytes (TILs)
Absent (n¼ 52) 41 (26) 9 (28) 0.41* 42 (27.6) 5 (18.5) 0.23* 36 (27) 12 (24) 0.19* 32 (25) 16 (30) 0.19*
Non-brisk (n¼ 126) 96 (62) 22 (69) 92 (60.5) 21 (77.8) 81 (60) 35 (71) 79 (62) 36 (67)
Brisk (n¼ 19) 18 (12) 1 (3) 18 (11.8) 1 (3.7) 17 (13) 2 (4) 16 (13) 2 (4)
The number of observations, percentage shown in parentheses (%), and the respective P-values are shown resultant from Pearson’s w2-test
of association (w2), or Fisher’s exact test, in which the frequency of observations in a cell was less than 5 (indicated with *). Statistically significant
P-values are indicated by bold font.
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Table 2 The table shows the association between microvessel density, macrophage count, blood vessel invasion and haematoxylin and
eosin-determined vascular invasion with clinicopathological variables in melanoma
Category Microvessel density Macrophage count Blood vessel invasion Vascular invasion
n (%) n (%) n (%) Haematoxylin and eosin n (%)
Low High P-value Low High P-value Absent Present P-value Absent Present P-value
Gender
Female (n¼ 99) 44 (46) 45 (47) 0.88 51 (54) 44 (44) 0.18 86 (47) 3 (37) 0.73* 90 (49) 6 (37) 0.37
Male (n¼ 103) 51 (53) 50 (53) 44 (46) 56 (56) 96 (53) 5 (62) 93 (51) 10 (62)
Sentinal node biopsy (SNB)
Negative (n¼ 70) 38 (40) 25 (26) 0.05 32 (34) 36 (36) 0.73 61 (34) 2 (25.0) 1.00* 68 (37) 2 (12) 0.06*
Positive (n¼ 132) 57 (60) 70 (74) 63 (66) 64 (64) 121 (66) 6 (75.0) 115 (63) 14 (87)
Relapse status
No (n¼134) 62 (68) 63 (67) 0.87 66 (73) 65 (66) 0.31 121 (68) 4 (50) 0.23* 126 (71) 8 (62) 0.09
Yes (n¼62) 29 (32) 31 (33) 25 (27) 34 (34) 56 (32) 4 (50) 52 (29) 5 (38)
Staging
IA/IB (n¼ 43) 29 (31) 10 (11) o0.001* 22 (24) 19 (20) 0.05* 39 (22) 0 (0) 0.47* 42 (24) 1 (7) 0.21*
IIA (n¼11) 6 (6) 3 (3) 5 (5) 6 (6) 9 (5) 0 (0) 10 (6) 1 (7)
IIB/IIC (n¼ 12) 2 (2) 9 (10) 2 (2) 10 (10) 10 (6) 1 (14) 12 (7) 0 (0)
IIIA (n¼88) 44 (47) 40 (44) 48 (52) 37 (38) 80 (45) 4 (57) 75 (42) 11 (73)
IIIB (n¼41) 12 (13) 28 (31) 15 (16) 25 (26) 38 (22) 2 (29) 38 (21) 2 (13)
Number of positive nodes
0 (n¼ 70) 38 (40) 25 (26) 0.06* 32 (34) 36 (36) 0.91* 61 (34) 2 (25) 0.41* 68 (37) 2 (12) 0.09*
1 or 2 (n¼123) 51 (54) 67 (71) 59 (62) 59 (59) 113 (62) 5 (62) 107 (58) 13 (81)
X3 (n¼ 9) 6 (6) 3 (3) 4 (4) 5 (5) 8 (4) 1 (12) 8 (4) 1 (6)
Melanoma site
Trunk (n¼ 73) 34 (36) 37 (39) 0.82 32 (34) 39 (39) 0.19 67 (37) 4 (50) 0.38* 65 (36) 7 (44) 0.62*
Leg (n¼ 67) 34 (36) 28 (29) 39 (41) 27 (27) 59 (32) 3 (37) 61 (33) 5 (31)
Arm (n¼ 45) 20 (21) 23 (24) 19 (20) 25 (25) 43 (24) 0 (0) 43 (23) 2 (12)
Head/neck (n¼17) 7 (7) 7 (7) 5 (5) 9 (9) 13 (7) 1 (12) 14 (8) 2 (12)
Histological subtype
Superficial spreading
(n¼ 141)
70 (78) 64 (72) 0.36* 73 (81) 63 (67) 0.03 130 (75) 4 (67) 0.37* 127 (74) 12 (80) 0.80*
Nodular (n¼ 37) 14 (16) 21 (24) 11 (12) 26 (28) 34 (20) 1 (17) 35 (20) 2 (13)
Other (n¼12) 6 (7) 4 (4) 6 (7) 5 (5) 9 (5) 1 (17) 10 (6) 1 (7)
Breslow thickness (mm)
p1 (n¼ 94) 53 (56) 34 (36) 0.02 55 (58) 34 (34) o0.001 84 (46) 3 (37) 0.89* 89 (49) 3 (19) 0.05*
41 p2 (n¼ 79) 32 (34) 42 (44) 35 (37) 43 (43) 70 (38) 4 (50) 69 (38) 9 (56)
42 p4 (n¼ 29) 10 (11) 19 (20) 5 (5) 23 (23) 28 (15) 1 (12) 25 (14) 4 (25)
Ulceration
No (n¼145) 80 (87) 54 (59) o0.001 79 (85) 60 (62) o0.001 130 (74) 4 (57) 0.39* 129 (73) 13 (87) 0.36*
Yes (n¼50) 12 (13) 37 (41) 14 (15) 36 (37) 46 (26) 3 (43) 48 (27) 2 (13)
Mitotic rate (per mm2)
o3 (n¼ 68) 41 (43) 21 (22) 0.002 36 (38) 27 (27) 0.005 61 (34) 1 (12) 0.29* 64 (35) 3 (19) 0.03*
3–7 (n¼ 62) 30 (32) 28 (30) 35 (37) 26 (26) 56 (31) 2 (25) 51 (28) 10 (62)
47 (n¼71) 24 (25) 25 (48) 23 (24) 47 (47) 64 (35) 5 (62) 67 (37) 3 (19)
Perineural infiltration
No (n¼186) 87 (97) 87 (100) 0.25* 86 (97) 94 (100) 0.11* 168 (98) 6 (100) 1.00* 170 (99) 13 (87) 0.02*
Yes (n¼3) 3 (3) 0 (0) 3 (3) 0 (0) 3 (2) 0 (0) 1 (1) 2 (13)
Regression
No (n¼171) 84 (88) 75 (81) 0.14 83 (88) 81 (82) 0.21 151 (84) 8 (100) 0.61* 155 (85) 13 (87) 1.00*
Yes (n¼29) 11 (12) 18 (19) 11 (12) 18 (18) 29 (16) 0 (0) 27 (15) 2 (13)
Microsatellites
No (n¼163) 79 (88) 74 (86) 0.73 78 (88) 80 (86) 0.75 149 (88) 4 (67) 0.18* 149 (88) 11 (73) 0.13*
Yes (n¼25) 11 (12) 12 (14) 11 (12) 13 (14) 21 (12) 2 (33) 21 (12) 4 (27)
Tumour infiltrating lymphocytes (TILs)
Absent (n¼ 52) 28 (30) 21 (22) 0.45 35 (37) 16 (16) 0.005 44 (25) 5 (62) 0.07* 48 (27) 4 (27) 0.59*
Non-brisk (n¼ 126) 56 (61) 63 (67) 51 (54) 71 (73) 116 (65) 3 (37) 113 (63) 11 (73)
Brisk (n¼ 19) 8 (9) 10 (11) 8 (9) 10 (10) 18 (10) 0 (0.0) 19 (11) 0 (0)
The number of observations, percentage shown in parentheses (%), and the respective P-values are shown resultant from Pearson’s w2-test
of association (w2), or Fisher’s exact test, in which the frequency of observations in a cell was less than 5 (indicated with *). Statistically significant
P-values are indicated by bold font.
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and the presence of microsatellites (w2¼ 7.69,
d.f.¼ 1, P¼ 0.006). In addition, vascular invasion
was also significantly associated with nodular
histological subtype (w2¼ 26.65, d.f.¼ 2, Po0.001;
Table 1).
Distribution of Lymphatic and Blood Vessels in
Cutaneous Melanoma
Immunohistochemistry using anti-D2-40 antibody
demonstrated consistent staining of lymphatic en-
dothelial cells. Lymphatic vessels were observed in
all peritumoural tissue, where this area was asses-
sable (100%, 181 out of 181). Intratumoural lym-
phatic vessels were observed in the majority of
tumours (86%, 165 out of 191). Peritumoural
lymphatic vessel density ranged from 0.009–0.198
per mm2 (median 0.060 per mm2) and intratumoural
lymphatic vessel density from 0.000–0.130 per mm2
(median 0.010 per mm2). Total lymphatic density
ranged from 0.004–0.266 per mm2 (median 0.077 per
mm2) and microvessel density ranged from 0.667–
9.000 (median 4.833). Lymphatic vessel and micro-
vessel density were not directly compared as
different assessment methods were used; required
due to the high frequency of blood vessels observed
in comparison with the relatively low level of
lymphatic vessels.24
Relationship between Lymphatic and Microvessel
Density and Clinicopathological Variables
Low intratumoural lymphatic vessel density was not
statistically associated with clinicopathological
variables, but was marginally associated with re-
lapse (w2¼ 4.91, d.f.¼ 1, P¼ 0.03) and tumour
infiltrating lymphocytes (TILs; w2¼ 6.08, d.f.¼ 2
P¼ 0.05). Total lymphatic vessel density was sig-
nificantly associated with the absence of TILs
(w2¼ 11.21, d.f.¼ 2, P¼ 0.004; Table 3).
High microvessel density was associated with
poor prognostic histological factors, being more
frequent in the presence of ulceration (w2¼ 17.79,
d.f.¼ 1, Po0.001) and high mitotic rate (w2¼ 12.91,
d.f.¼ 2, P¼ 0.002), and was positively associated
with stage (w2¼ 12.91, d.f.¼ 2, Po0.001). Further-
more high microvessel density was marginally
positively associated with positive sentinel node
biopsy (w2¼ 4.01, d.f.¼ 1, P¼ 0.05; Table 2).
Relationship between Macrophage Count and
Clinicopathological Data
The presence of tumour infiltrating macrophages
was investigated using anti-CD68 antibody, which is
able to detect both polarised type 1 (M1) and type 2
(M2) macrophages resulting from alternate differ-
entiation.28 High macrophage count was associated
with the presence of ulceration (w2¼ 12.23, d.f.¼ 1,
Po0.001), Breslow thickness (w2¼ 17.23, d.f.¼ 2,
Po0.001), mitotic rate (w2¼ 10.67, d.f.¼ 2,
P¼ 0.005) and the presence of non-brisk or brisk
TILs (w2¼ 10.53, d.f.¼ 2, P¼ 0.005). No other asso-
ciations with clinicopathological variables were
observed (Table 2).
Relationship between Vessel Density, Invasion and
Macrophage Count
Intratumoural lymphatic density was associated
with intratumoural lymphatic vessel invasion
(w2¼ 8.05, d.f.¼ 1, P¼ 0.005), but not peritumoural
invasion. Blood microvessel density was associated
with intratumoural, peritumoural and any lympha-
tic invasion (w2¼ 8.08, d.f.¼ 1, P¼ 0.004; w2¼ 6.65,
d.f.¼ 1, P¼ 0.010; w2¼ 14.77, d.f.¼ ,1 Po0.001,
respectively). A high macrophage count was sig-
nificantly associated with the presence of any
lymphatic vessel invasion (w2¼ 9.15, d.f.¼ 1,
P¼ 0.002), blood microvessel density (w2¼ 8.94,
d.f.¼ 1, P¼ 0.003) and immunohistochemically
determined vascular invasion (w2¼ 8.66, d.f.¼ 1,
P¼ 0.003), indicating the likely importance of
macrophage in the process of tumour vascularisa-
tion and lymphatic dissemination.
Clinical Outcome and Vessel Density, Invasion and
Macrophage Involvement
None of the variables assessed in this study were
statistically associated with relapse-free or overall
survival in univariate analysis, and were therefore
not assessed in multivariate analysis.
Discussion
This study analysed vessel invasion and density,
both blood and lymphatic in primary melanomas as
prognostic markers. In addition, the contribution of
tumour-associated macrophages to this process was
evaluated. To our knowledge, this is one of the
largest studies of its type so far, which benefits from
having a large proportion of positive sentinel node
biopsy patients compared with previous studies,
and also from a single expert melanoma pathologist’
review of the primary melanoma and sentinel node
biopsy pathology.
Discrepancies exist between vascular invasion
determined by immunohistochemistry and H&E,
principally due to difficulties in determining the
vessel endothelium surrounding tumour emboli or
confounding fixation-related artefacts in H&E-
stained tissues. The detection rates of vascular
invasion determined in H&E-stained tissues in
comparison with lymphatic vessel invasion deter-
mined by immunohistochemistry in previously
published studies have ranged from 0–16,29 0–17,15
0–23,9 3.1–21.913 and 4–37%.14 In the current study,
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Table 3 The table shows the association between lymphatic density measures and clinicopathological variables in melanoma
Category Lymphatic density
Intratumoural n (%) Peritumoural n (%) Total n (%)
Low High P-value Low High P-value Low High P-value
Gender
Female (n¼99) 48 (51) 44 (46) 0.52 45 (51) 44 (48) 0.71 50 (52) 42 (44) 0.28
Male (n¼103) 47 (49) 52 (54) 44 (49) 48 (52) 46 (48) 53 (56)
Sentinal node biopsy (SNB)
Negative (n¼70) 38 (40) 28 (29) 0.12 35 (39) 31 (34) 0.43 36 (37) 30 (32) 0.39
Positive (n¼132) 57 (60) 68 (71) 54 (61) 61 (66) 60 (62) 65 (68)
Relapse status
No (n¼134) 57 (61) 71 (76) 0.03 61 (70) 63 (69) 0.90 61 (66) 67 (72) 0.34
Yes (n¼ 62) 36 (39) 22 (24) 26 (30) 91 (31) 32 (34) 26 (28)
Staging
IA/IB (n¼43) 23 (26) 17 (18) 0.69 23 (27) 17 (19) 0.58 22 (24) 18 (19) 0.78
IIA (n¼11) 6 (7) 5 (5) 6 (7) 5 (6) 6 (7) 5 (5)
IIB/IIC (n¼ 12) 6 (7) 5 (5) 5 (6) 6 (7) 5 (5) 6 (6)
IIIA (n¼88) 38 (42) 45 (48) 33 (38) 44 (50) 37 (41) 46 (49)
IIIB (n¼41) 17 (19) 22 (23) 19 (22) 16 (18) 21 (23) 18 (19)
Number of positive nodes
0 (n¼70) 38 (40) 28 (29) 0.31* 35 (39) 31 (34) 0.35* 36 (37) 30 (32) 0.37*
1 or 2 (n¼ 123) 53 (56) 63 (66) 48 (54) 58 (63) 54 (56) 62 (65)
X3 (n¼9) 4 (4) 5 (5) 6 (7) 3 (3) 6 (6) 3 (3)
Melanoma site
Trunk (n¼73) 40 (42) 32 (33) 0.27 35 (39) 32 (35) 0.44 35 (36) 37 (39) 0.12
Leg (n¼67) 25 (26) 38 (40) 30 (34) 29 (32) 35 (36) 28 (29)
Arm (n¼45) 23 (24) 19 (20) 20 (22) 21 (23) 23 (24) 19 (20)
Head/neck (n¼17) 7 (7) 7 (7) 4 (4) 10 (11) 3 (3) 11 (12)
Histological subtype
Superficial spreading (n¼141) 65 (75) 70 (75) 0.21* 68 (79) 64 (74) 0.72 67 (75) 68 (75) 0.55*
Nodular (n¼37) 14 (16) 20 (22) 13 (15) 17 (20) 15 (17) 19 (21)
Other (n¼12) 8 (9) 3 (3) 5 (6) 5 (6) 7 (8) 4 (4)
Breslow thickness (mm)
p1 (n¼94) 48 (51) 40 (42) 0.08 44 (49) 43 (47) 0.83 46 (48) 42 (44) 0.13
41 p2 (n¼79) 30 (32) 45(47) 32 (36) 37 (40) 32 (33) 43 (45)
42 p4 (n¼29) 17 (18) 11 (12) 13 (15) 12 (13) 18 (19) 10 (11)
Ulceration
No (n¼145) 69 (77) 67 (71) 0.41 66 (76) 64 (74) 0.73 69 (75) 67 (73) 0.74
Yes (n¼ 50) 21 (23) 27 (29) 21 (24) 23 (26) 23 (25) 25 (27)
Mitotic rate (per mm2)
o3 (n¼68) 38 (40) 26 (27) 0.15 36 (41) 26 (28) 0.20 39 (41) 25 (26) 0.08
3–7 (n¼ 62) 26 (28) 32 (33) 24 (27) 31 (34) 24 (25) 34 (36)
47 (n¼71) 30 (32) 38 (40) 28 (32) 35 (38) 32 (34) 36 (38)
Perineural infiltration
No (n¼186) 85 (97) 90 (100) 0.12* 81 (96) 85 (100) 0.12* 86 (97) 89 (100) 0.25*
Yes (n¼ 3) 3 (3) 0 (0) 3 (4) 0 (0) 3 (3) 0 (0)
Regression
No (n¼171) 78 (84) 82 (85) 0.77 75 (86) 75 (82) 0.40 81 (86) 79 (83) 0.57
Yes (n¼ 29) 15 (16) 14 (15) 12 (14) 17 (18) 13 (14) 16 (17)
Microsatellites
No (n¼163) 76 (86) 79 (89) 0.63 69 (83) 78 (92) 0.09 74 (84) 81 (91) 0.16
Yes (n¼ 25) 12 (14) 10 (11) 14 (17) 7 (8) 14 (16) 8 (9)
Tumour infiltrating lymphocytes (TILs)
Absent (n¼52) 32 (34) 18 (19) 0.05 28 (32) 19 (21) 0.21 35 (38) 15 (16) 0.004
Non-brisk (n¼ 126) 54 (58) 64 (68) 51 (59) 62 (67) 50 (54) 68 (72)
Brisk (n¼19) 7 (8) 12 (13) 8 (9) 11 (12) 8 (9) 11 (12)
The number of observations, percentage shown in parentheses (%), and the respective P-values are shown resultant from Pearson’s w2-test
of association (w2), or Fisher’s exact test, in which the frequency of observations in a cell was less than 5 (indicated with *). Statistically significant
P-values are indicated by bold font.
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an increase from 8–30% total vascular (both lym-
phatic and blood) invasion was observed, or 27%, if
only lymphatic vessel invasion is considered. Pre-
vious work and the data presented here show that
assessment of vascular invasion using conventional
H&E-stained tissue is fraught with difficulty, with a
high false positive and negative detection rate.
Reported detection rates for lymphatic vessel
invasion are 16,12,29 17,15 21.9,13 23,9 33,10,11 37,14
476 and 63%7 in melanoma. In this study, we
demonstrated lymphatic vessel invasion in 27% of
cases. A preference of lymphatic over blood vessel
invasion has been reported previously with varying
frequencies of blood vessel to lymphatic vessel
invasion of 3–16,12 4.7–3311 and 43–47%,6 respec-
tively; our current study demonstrates that lympha-
tic vessel invasion occurs more frequently than
blood vessel invasion (27 vs 4%). In addition, three
of the eight cases identified as having blood vessel
invasion also had lymphatic vessel invasion. D2-40
was used to stain lymphatic vessels as it stains
lymphatic cells, but also some other cell types such
as mesothelial and ependymal cells; although
prospero-related homeobox gene-1 (prox-1) specifi-
cally stains lymphatic cells, it stains only the
lymphatic nuclei, making interpretation more diffi-
cult, and VEGFR-3 is expressed on angiogenic blood
vessels in tumours.30
It is unclear as to what would cause preferential
lymphatic invasion, in tumours with a rich vascular
network. Interestingly, dermal lymphatic endothe-
lial cells, not blood endothelial cells, express SLC/
CCL21 the ligand for the CC chemokine receptor 7
expressed on melanoma cells, and this ligand/
receptor interaction is implicated in the recruitment
of mature dendritic cells from interstitial spaces to
lymphatic vessels.31 In-vivo murine models have
suggested that the intratumoural lymphatic network
may be non-functional and lymphatic vessels at the
tumour margin may be enough for metastasis.32
Previous studies have demonstrated an associa-
tion between intratumoural lymphatic vessel den-
sity and sentinel node biopsy positivity (37
patients;33 45 patients5). Furthermore, the use of
lymphatic density has been incorporated into the
Shield’s Index, also including lymphatic vessel
invasion and Breslow thickness, which can be used
to predict metastasis in melanoma patients.6,7 In the
current study, no associations were observed with
either lymphatic vessel density, or microvessel
density and clinical outcome; however, microvessel
density was associated with markers of more
aggressive disease including ulceration, tumour
stage and mitotic rate. Studies that have previously
investigated lymphatic vessel density in melanoma
have focussed on investigating associations with
clinical outcome; of those that have examined
links with clinicopathological variables associa-
tions between lymphatic vessel density and age,3,5
the presence of inflammatory infiltrate,5,8 positive
sentinel lymph node,5 tumour stage4 and tumour
thickness3 have been described. Previous studies
have not shown an association between lymphatic
vessel density and ulceration.3,5,6 Associations
between microvessel density and Clark’s level4 and
tumour stage4 have also been previously reported.
The presence of a high macrophage count was
significantly associated with the presence of any
lymphatic vessel invasion, high microvessel density
and total immunohistochemically determined vas-
cular invasion. Previous studies have highlighted
associations between VEGF-C, an activator of lym-
phangiogenesis and lymphatic vessel density, and it
may be possible that a putative macrophage effect on
vessels might be mediated in part through this
growth factor.33,34 VEGF-C expression by the tumour
has been shown to increase lymphangiogenesis in
in-vivo murine models,32,35 but also associated with
the recruitment macrophages via the VEGFR-3
receptor, which is also found on the surface of
lymphatic vessels.35 In addition to VEGF-C, there
may be a number of cytokines involved in promoting
lymphatic vessel invasion as observed in in-vitro
studies. Nitric oxide (NO) has been implicated in
the process of lymphangiogenesis, and the expres-
sion of inducible NO synthase in melanoma is
associated with lymphatic vessel density.36 Interest-
ingly, a study by the same group suggested that
inducible NO synthase expressed by tumour-asso-
ciated macrophages may contribute to elevated
NO.37 Jensen et al20 investigated the presence of
CD68-stained macrophages at the invasive front of
melanoma tumours, in tumour nests and in tumour
stroma, and showed an association with poor overall
survival and linked the presence of macrophages in
tumour nests and stroma to patient age and median
thickness. No association with the presence of
macrophages and clinical outcome was observed in
the current study; however, there was a significant
association between a high macrophage count
and ulceration, Breslow thickness, mitotic rate
and tumour infiltrating lymphocytes. Molecular
characterisation of sentinel nodes, with and with-
out tumour metastasis, and non-sentinel nodes,
revealed an elevated gene expression of interleukin
13, leptin, lymphotoxin b-receptor and macrophage
inflammatory protein 1b, highlighting the role of
cytokine profile in subsequent nodal metastasis, in
particular, MIP1B which has been shown to increase
invasion of uveal melanoma.38,39
In conclusion, data from the current study shows
that in melanoma, vascular invasion occurs pre-
dominantly via lymphatic vessels. Furthermore, the
data demonstrate that vascular invasion is more
accurately detected in immunohistochemistry-
stained-tissue using specific endothelial markers,
than conventional assessment in H&E-stained tis-
sue. Vascular invasion was associated with factors
indicative of a poor prognosis including stage,
increased Breslow thickness and ulceration.
Lymphatic vessel density was associated with
microvessel density, and macrophage count was
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associated with ulceration and mitotic rate. Micro-
vessel density, lymphatic vessel density, lymphatic
and blood vessel invasion were not associated with
relapse-free or overall survival. The observation that
vessel characteristics investigated were not asso-
ciated with relapse-free or overall survival was
unexpected due to their strong association with
known adverse prognostic histological features of
primary melanoma; however, this may attest to the
value of existing histological biomarkers. Because of
the retrospective nature of the data collection, the
follow-up time of this study was not standardised
and varied from 1 day to 111.7 months, which is a
limitation of this study. Perhaps, most interestingly,
these results suggest that a high macrophage count
is associated with markers of neovascularisation and
corresponding primary tumour growth, and the
suggestion is therefore that macrophages may have
a role in vascular neogenesis. A high macrophage
count may also have a role in cancer cell dissemina-
tion by regulating preferential invasion of lymphatic
over blood vessels, as an association was observed
between lymphatic vessel invasion and macrophage
count.
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